BRAF and neoplasm: In the BRAF mutant context, all but the weakest clinically realized combinations of Belvarafenib and Cobimetinib perform similarly, inhibiting tumor growth, as shown by the corresponding GR metric values, without significant synergistic effects, as shown by low Bliss excess values (Figure 5b left).